An overview of small-molecule inhibitors of VEGFR signaling
The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Signal transduction by receptors with tyrosine kinase activity
Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Angiogenesis in life, disease and medicine
Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,482
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122 · cited 1×
“The expression of VEGF has also been observed following inactivation of the TP53”
BackgroundAngiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 1×
“In neoplasms, tumor-derived factors promote angiogenesis, which includes multiple processes such as cell division, migration, normal growth patterns and progression until vessels can function”
BackgroundTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
Fong, G.-H., Rossant, J., Gertsenstein, M., & Breitman, M. L. (1995) · Nature · doi:10.1038/376066a0 · Cited by 2,606
Ferrara, N., & Henzel, W. J. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)92678-8 · Cited by 2,268
Vascular Permeability Factor, an Endothelial Cell Mitogen Related to PDGF
Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., & Connolly, D. T. (1989) · Science · doi:10.1126/science.2479987 · Cited by 2,061
VEGF as a Key Mediator of Angiogenesis in Cancer
Carmeliet, P. (2005) · Oncology · doi:10.1159/000088478 · Cited by 1,768
VEGF-targeted therapy: mechanisms of anti-tumour activity
Ellis, L. M., & Hicklin, D. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2403 · Cited by 1,673
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
VEGF Inhibition and Renal Thrombotic Microangiopathy
Eremina, V., Jefferson, J. A., Kowalewska, J., Hochster, H., Haas, M., Weisstuch, J., Richardson, C., Kopp, J. B., Kabir, M. G., Backx, P. H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707330 · Cited by 1,504
Growth factor signaling by receptor tyrosine kinases
Schlessinger, J., & Ullrich, A. (1992) · Neuron · doi:10.1016/0896-6273(92)90177-f · Cited by 1,430
Karkkainen, M. J., Haiko, P., Sainio, K., Partanen, J., Taipale, J., Petrova, T. V., Jeltsch, M., Jackson, D. G., Talikka, M., Rauvala, H., et al. (2004) · Nature Immunology · doi:10.1038/ni1013 · Cited by 1,421
Protein Tyrosine Kinase Structure and Function
Hubbard, S. R., & Till, J. H. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.373 · Cited by 1,171
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia
Levy, A. P., Levy, N. S., Wegner, S., & Goldberg, M. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13333 · Cited by 1,067
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056 · cited 1×
“Drugs that target the VEGF pathway block angiogenesis, can induce tumor shrinkage and/or necrosis and prevent tumor growth”
BackgroundRole of Tyrosine Kinase Inhibitors in Cancer Therapy
Arora, A., & Scholar, E. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,014
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
VEGF-receptor signal transduction
Cross, M. J., Dixelius, J., Matsumoto, T., & Claesson-Welsh, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00193-2 · Cited by 864
Makinen, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.17.4762 · Cited by 845
Relf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 833
Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 798
The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease.
Holmes, D. I. R., & Zachary, I. C. (2005) · Genome biology · doi:10.1186/gb-2005-6-2-209 · Cited by 779
Takahashi, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.11.2768 · Cited by 749
Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., Smith, N. R., James, N. H., Dukes, M., Curwen, J. O., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4409 · Cited by 714
Vascular endothelial growth factor and its receptors
Klagsbrun, M., & A. D'Amore, P. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(96)00027-5 · Cited by 682
Post-transcriptional Regulation of Vascular Endothelial Growth Factor by Hypoxia
Levy, A. P., Levy, N. S., & Goldberg, M. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.5.2746 · Cited by 629
Vascular Endothelial Growth Factor as a Target for Anticancer Therapy
Ferrara, N. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_1-2 · Cited by 574
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Takahashi, T., Ueno, H., & Shibuya, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202527 · Cited by 571
Nagy, J. A., Vasile, E., Feng, D., Sundberg, C., Brown, L. F., Detmar, M. J., Lawitts, J. A., Benjamin, L., Tan, X., Manseau, E. J., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021244 · Cited by 559
Fujio, Y., & Walsh, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16349 · Cited by 553
Biology of vascular endothelial growth factors
Roy, H., Bhardwaj, S., & Ylä-Herttuala, S. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.03.087 · Cited by 537
Jiang, B., Agani, F. H., Passaniti, A., & Semenza, G. L. (1997) · PubMed · Cited by 532
Maher, E. R., & Kaelin, W. G. (1997) · Medicine · doi:10.1097/00005792-199711000-00001 · Cited by 528
VEGF Receptor Signal Transduction
Matsumoto, T., & Claesson-Welsh, L. (2001) · Science's STKE · doi:10.1126/stke.2001.112.re21 · Cited by 502
Senger, D. R., Connolly, D. T., Water, L. V. D., Feder, J., & Dvorak, H. F. (1990) · PubMed · Cited by 500
Burstein, H. J., Elias, A. D., Rugo, H. S., Cobleigh, M. A., Wolff, A. C., Eisenberg, P. D., Lehman, M., Adams, B. J., Bello, C. L., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5375 · Cited by 489
Rugo, H. S., Herbst, R. S., Liu, G., Park, J. W., Kies, M. S., Steinfeldt, H. M., Pithavala, Y. K., Reich, S. D., Freddo, J. L., & Wilding, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.192 · Cited by 486
Abedi, H., & Zachary, I. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.24.15442 · Cited by 471
Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis
Karkkainen, M. J., & Petrova, T. V. (2000) · Oncogene · doi:10.1038/sj.onc.1203855 · Cited by 427
Strumberg, D., Clark, J. W., Awada, A., Moore, M. J., Richly, H., Hendlisz, A., Hirte, H. W., Eder, J. P., Lenz, H.-J., & Schwartz, B. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-426 · Cited by 419
Phase I Trial of Pazopanib in Patients with Advanced Cancer
Hurwitz, H. I., Dowlati, A., Saini, S., Savage, S., Suttle, A. B., Gibson, D. M., Hodge, J. P., Merkle, E. M., & Pandite, L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2740 · Cited by 418
Vascular Endothelial Growth Factor Receptor-3 in Lymphangiogenesis in Wound Healing
Paavonen, K., Puolakkainen, P., Jussila, L., Jahkola, T., & Alitalo, K. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65021-3 · Cited by 398
Traxler, P., Allegrini, P. R., Brandt, R., Brueggen, J., Cozens, R., Fabbro, D., Grosios, K., Lane, H. A., McSheehy, P., Mestan, J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3681 · Cited by 320
Hennequin, L. F., Stokes, E. S. E., Thomas, A. P., Johnstone, C., Plé, P. A., Ogilvie, D. J., Dukes, M., Wedge, S. R., Kendrew, J., & Curwen, J. O. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011022e · Cited by 311
Holden, S. N., Eckhardt, S. G., Basser, R., de Boer, R., Rischin, D., Green, M., Rosenthal, M. A., Wheeler, C., Barge, A., & Hurwitz, H. I. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi247 · Cited by 304
Drevs, J., Siegert, P., Medinger, M., Mross, K., Strecker, R., Zirrgiebel, U., Harder, J., Blum, H., Robertson, J., Jürgensmeier, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2066 · Cited by 303
DVORAK, H. F. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01361.x · Cited by 296
Polverino, A., Coxon, A., Starnes, C., Diaz, Z., DeMelfi, T., Wang, L., Bready, J., Estrada, J., Cattley, R., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4665 · Cited by 287
Kuenen, B. C., Rosen, L. S., Smit, E. F., Parson, M., Levi, M. M., Ruijter, R., Huisman, H., Kedde, M. A., Noordhuis, P., van der Vijgh, W. J. F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1657 · Cited by 279
Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation
Meadows, K. N., Bryant, P., & Pumiglia, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108069200 · Cited by 278
Shu, X., Wu, W., Mosteller, R. D., & Broek, D. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.22.7758-7768.2002 · Cited by 278
Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1)
Shibuya, M. (2001) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00026-7 · Cited by 260
Structural analysis of receptor tyrosine kinases
Hubbard, S. R. (1999) · Progress in Biophysics and Molecular Biology · doi:10.1016/s0079-6107(98)00047-9 · Cited by 239
Pazopanib: A novel multitargeted tyrosine kinase inhibitor
Sonpavde, G., & Hutson, T. E. (2007) · Current Oncology Reports · doi:10.1007/s11912-007-0007-2 · Cited by 203
Protein Kinase InhibitorsThe Tyrosine-Specific Protein Kinases
Lawrence, D. S., & Niu, J. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00052-1 · Cited by 198
Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Curwen, J., Hennequin, L. F., Thomas, A., Stokes, E. S. E., Curry, B. J., Richmond, G., et al. (2000) · PubMed · Cited by 192
Steeghs, N., Gelderblom, H., Roodt, J. O. '., Christensen, O., Rajagopalan, P., Hovens, M., Putter, H., Rabelink, T. J., & de Koning, E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5050 · Cited by 190
Rosen, L. S., Kurzrock, R., Mulay, M., Van Vugt, A., Purdom, M., Ng, C., Silverman, J., Koutsoukos, A., Sun, Y.-N., Bass, M. B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8170 · Cited by 188
The development and therapeutic potential of protein kinase inhibitors
Cohen, P. (1999) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)80067-2 · Cited by 182
VEGF/VEGFR signalling as a target for inhibiting angiogenesis
Kiselyov, A., Balakin, K. V., & Tkachenko, S. E. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.1.83 · Cited by 172
Dayanir, V., Meyer, R. D., Lashkari, K., & Rahimi, N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009128200 · Cited by 170
Korpelainen, E., Karkkainen, M. J., Gunji, Y., Vikkula, M., & Alitalo, K. K. (1999) · Oncogene · doi:10.1038/sj.onc.1202288 · Cited by 165
Mross, K., Drevs, J., Müller, M., Medinger, M., Marmé, D., Hennig, J., Morgan, B., Lebwohl, D., Masson, E., Ho, Y.-Y., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.005 · Cited by 165
Boeuf, F. L., Houle, F., & Huot, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405493200 · Cited by 151
Are tumours angiogenesis‐dependent?
Verheul, H. M. W., Voest, E. E., & Schlingemann, R. O. (2003) · The Journal of Pathology · doi:10.1002/path.1473 · Cited by 143
Ouyang, B., Knauf, J. A., Smith, E. P., Zhang, L., Ramsey, T., Yusuff, N., Batt, D. B., & Fagin, J. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1729 · Cited by 138
Sarker, D., Molife, R., Evans, T. R. J., Hardie, M., Marriott, C., Butzberger-Zimmerli, P., Morrison, R., Fox, J. A., Heise, C., Louie, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1466 · Cited by 138
Underiner, T. L., Ruggeri, B., & Gingrich, D. E. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043455756 · Cited by 127
Sakai, R., Henderson, J. T., O’Bryan, J. P., Elia, A., Saxton, T. M., & Pawson, T. J. (2000) · Neuron · doi:10.1016/s0896-6273(00)00156-2 · Cited by 109
Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors
Manley, P. W., Furet, P., Bold, G., Brüggen, J., Mestan, J., Meyer, T., Schnell, C., Wood, J. M., Haberey, M., Huth, A., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020899q · Cited by 109
von Hippel-Lindau disease: Clinical and molecular perspectives
Clifford, S. C., & Maher, E. R. (2001) · Advances in cancer research · doi:10.1016/s0065-230x(01)82003-0 · Cited by 106
Klohs, W. D., Fry, D. W., & Kraker, A. J. (1997) · Current Opinion in Oncology · doi:10.1097/00001622-199711000-00012 · Cited by 106
Mross, K. B., Steinbild, S., Baas, F., Gmehling, D., Radtke, M., Voliotis, D., Brendel, E., Christensen, O., & Unger, C. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.08.032 · Cited by 104
Wang, J., Zhang, X., & Groopman, J. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314015200 · Cited by 91
Garton, A. J., Crew, A. P. A., Franklin, M. R., Cooke, A. R., Wynne, G. M., Castaldo, L., Kahler, J., Winski, S. L., Franks, A., Brown, E. N., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2873 · Cited by 85
A phase I surrogate endpoint study of SU6668 in patients with solid tumors
Xiong, H. Q., Herbst, R. S., Faria, S. C., Scholz, C. R., Davis, D. W., Jackson, E. F., Madden, T. L., McConkey, D. J., Hicks, M. E., Hess, K. R., et al. (2004) · Investigational New Drugs · doi:10.1023/b:drug.0000036688.96453.8d · Cited by 84
WARNER, A. J., Lopez‐Dee, J., KNIGHT, E. L., Feramisco, J. R., & Prigent, S. A. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3470501 · Cited by 80
Ryan, C. J., Stadler, W. M., Roth, B. J., Hutcheon, D., Conry, S., Puchalski, T. A., Morris, C. Q., & Small, E. J. (2007) · Investigational New Drugs · doi:10.1007/s10637-007-9050-y · Cited by 71
Ligand-binding sites in Ig-like domains of receptor tyrosine kinases
Wiesmann, C., Muller, Y. A., & de Vos, A. M. (2000) · Journal of Molecular Medicine · doi:10.1007/s001090000082 · Cited by 41
Marathe, P. H., Kamath, A. V., Zhang, Y., D’Arienzo, C. J., Bhide, R. S., & Fargnoli, J. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1002-0 · Cited by 39
Taylor, A. P., Osorio, L., Craig, R., Raleigh, J. A., Ying, Z., Goldenberg, D. M., & Blumenthal, R. D. (2002) · PubMed · Cited by 24
Cohen, R. B., Langer, C. J., Simon, G. R., Eisenberg, P. D., Hainsworth, J. D., Madajewicz, S., Cosgriff, T. M., Pierce, K. J., Xu, H., Liau, K., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0352-0 · Cited by 16
Salzberg, M. O., Pless, M., Rochlitz, C. F., Ambrus, K., Scigalla, P., & Herrmann, R. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-4061-z · Cited by 12
(1995) · PubMed
Cited by
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
“A second class of approved inhibitors (sunitinib, sorafenib and pazopanib) include oral small-molecule tyrosine kinase inhibitors (TKIs) that target VEGFRs, platelet-derived growth factor (PDGF) receptors, and other kinases including KIT, Ret, BRAF and Flt-3”
BackgroundThe parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481
VEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Saharinen, P., Eklund, L., Pulkki, K., Bono, P., & Alitalo, K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.015 · Cited by 478
CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?
Duda, D. G., Kozin, S. V., Kirkpatrick, N. D., Xu, L., Fukumura, D., & Jain, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2636 · Cited by 395
Metadata
- Authors
- Ivy, S. P., Wick, J. Y., & Kaufman, B. M.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2009-09-08
- Volume
- 6
- Issue
- 10
- Pages
- 569-579
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2081887573
- Cited by
- 350
- References
- 92
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.